Inside the UAE cancer pilot
BioTwin runs its first clinical cancer pilot in the United Arab Emirates, with Cleveland Clinic Abu Dhabi. Here is what it delivers today and what it does not.
The partnership
BioTwin partners with Cleveland Clinic Abu Dhabi on cancer screening decision assistance. In the UAE, the program covers six cancers: breast, colorectal, lung, pancreatic, prostate and ovarian cancer, with breast and colorectal cancer as the priority. Patients are referred by their physicians at the clinic, not the other way around. Results are returned to the referring physician, who interprets them in the context of the patient's full medical record. BioTwin does not deliver clinical findings directly to patients in the pilot. The program operates under the regulatory framework of the United Arab Emirates, under the authority of the Department of Health, Abu Dhabi.
Why breast and colorectal first
Both cancers have well understood Bio-Signatures. BioTwin's technology is being studied for regulated clinical decision assistance. Giving priority to the two cancers where the science is strongest lets BioTwin validate its virtual twin under clinical supervision, while lung, pancreatic, prostate and ovarian cancer complete the program. Every result delivered to a physician must be backed by the strongest available evidence.
What this means for TwinMe customers in the US and Canada
Clinical availability: UAE only, through participating physicians in authorized settings. BioTwin is not authorized as a medical device in Canada or the United States. The UAE pilot is a pilot, not a direct-to-consumer product line. Wellness programs are offered separately through TwinMe. If regulators in other jurisdictions authorize new uses, any additional pilot will follow the same physician-referred path first.